Citius Oncology Announces U.S. Commercial Launch of LYMPHIR(TM), a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

Citius Oncology Expands LYMPHIR(TM) Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
Citius Oncology to Advance Commercial Launch of LYMPHIR(TM) with Verix AI Integration
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR(TM) Commercial Launch
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR(TM)
Citius Oncology Establishes International Access to LYMPHIR(TM) via Named Patient Programs in Southern Europe
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.